Soy petition withdrawal
This article was originally published in The Tan Sheet
Executive Summary
The Solae Company is formally withdrawing from further consideration the qualified health claim petition linking soy protein consumption to prevention of cancer, the company confirms in a recent letter to the agency. "The nutrition science pertaining to the health benefits of soy protein is substantial and continues to evolve," and "serves as a catalyst for futher scientific investigation," Solae states. The firm has "closely monitored recent FDA actions with respect to certain qualified health claims. With the benefit of this information, the Solae Company respectifully reserves the option to resubmit a qualified health claim petition centering on soy protein and cancer prevention in the future." The firm also is "most appreciative of the deliberate fashion in which FDA reviewed" its petition, which it announced was under review in April 2004 (1"The Tan Sheet" April 19, 2004, In Brief)...
You may also be interested in...
Soy claims
Solae Company's petition for health claims that soy protein-based foods may reduce the risk of certain types of cancer is being reviewed by FDA, the St. Louis based firm announced April 16. The petition cites 58 studies supporting the relationships, Solae says. The DuPont/Bunge joint venture is "looking forward to the agency's evaluation"...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.